Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell ...

Vertex Pharmaceuticals Inc. closed $111.56 below its 52-week high ($519.88), which the company achieved on November 8th.

Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and ...

Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with ...

Vertex VERX shares have skyrocketed 107.3% in the past 12 months, outperforming the Zacks Computer Technology sector, Zacks ...

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...

Vertex partners with Orna Therapeutics to develop in vivo gene editing treatments for sickle cell disease and beta ...

So VeriSign's still-low invested capital supports its high current ROIC. On an adjusted basis, the company's ROIC was 4.4% for 2023, with a five-year average of 3.9%, according to the data provided by ...

New research by Security Intelligence has revealed security risks in MLOps platforms including Azure ML, BigML and Google ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/97.X7yKkA3Y.js ...